Context

TxCell (Euronext-listed) developed a proprietary Treg technological platform for the treatment of severe inflammatory and autoimmune diseases.

Sangamo Therapeutic (NYSE-listed) is a leader in gene therapy and recently entered into a partnership with Gilead to develop the next generation CAR-T therapies in oncology.

Sangamo expects to submit a clinical trial authorization application in Europe for TxCell’s investigational product candidate for solid organ transplant and to use its ZFN gene editing technology to develop next-generation autologous and allogeneic CAR-Treg cell therapies.

About TxCell

TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need. TxCell is targeting transplantation as well as a range of autoimmune diseases (both T-cell and B-cell-mediated), such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases or inflammatory skin diseases. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 46 employees.

Discover TxCell

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using Sangamo’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy

Discover Sangamo Therapeutics

Olivier Garnier

Investment Banking

Dr. Anne Moore

Investment Banking

Cosme Rosellini

Investment Banking

Hervé Ronin

Investment Banking

Romain Ellul

Investment Banking

Dr. Mickael Dubourd

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center